Business Context and Reporting Period
This Form 8-K Current Report was filed by Alnylam Pharmaceuticals, Inc. on June 10, 2015, covering events occurring on June 8, 2015. The filing primarily addresses the appointment of a new senior executive officer.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margin, debt, or liquidity metrics. It focuses exclusively on executive compensation details:
- Annual Base Salary: $425,000
- Initial Sign-on Bonus: $200,000
- Subsequent Bonus: $100,000 (payable after the first anniversary)
- Annual Cash Bonus Target: 40% of base salary
- Stock Option Grant: 140,000 shares at an exercise price of $129.97 per share
Material Changes
Effective June 8, 2015, the Company appointed David-Alexandre Gros, M.D., as Senior Vice President, Chief Business Officer. Dr. Gros joins from Sanofi, where he served as Executive Vice President and Chief Strategy Officer. This appointment represents a material change in the Company's principal officers.
Outlook, Risks, and Unusual Items
Management Commentary: The appointment is intended to strengthen the Company's business development and strategic leadership. Dr. Gros brings experience in corporate strategy, licensing, M&A, and alliance management.
Compensation Contingencies: The sign-on and subsequent bonuses are subject to clawback provisions. If Dr. Gros voluntarily terminates employment (other than for good reason) or is terminated for cause within 12 months of receiving the Initial Bonus, or within months 12-24 of the Subsequent Bonus, he must repay the respective bonus in full.
Stock Option Vesting: The 140,000 share option grant vests 25% on the first anniversary of the grant date, with the remainder vesting ratably over the following three years.
Investor Verification Checklist
- Verify the impact of the new Chief Business Officer on the Company's pipeline and partnership strategy.
- Review the Company's 2015 Annual Incentive Program to understand the specific performance goals tied to the 40% bonus target.
- Monitor the vesting schedule of the 140,000 stock options granted to Dr. Gros.
- Confirm the Company's cash position to ensure it can support the immediate $200,000 sign-on bonus and future compensation obligations.